December 2010. Volume 6. Number 4

Palivizumab immunization against respiratory syncytial virus is only cost-effective in infants with bronchopulmonary dysplasia and in the months with high-risk of infection

 
 
 
 
 
 
 
 
 
 
Rating: 4.67 (3 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Rietveld E, Steyerberg EW, Polder JJ, Veeze HJ, Vergouwe Y, Huysman MWA, et al. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis. Arch Dis Child. 2010;95:493-8.
Reviewers: González de Dios J1, Ochoa Sangrador C2.
1Departamento de Pediatría. Hospital General Universitario de Alicante. España.
2Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
Correspondence: Javier González de Dios. Email: javier.gonzalezdedios@gmail.com
Reception date: 10/10/2010
Acceptance date: 19/10/2010
Publication date: 21/10/2010

Abstract

Authors´conclusions: a restrictive immunization policy with palivizumab is recommended, verifying an appropriate cost-effectiveness ratio only immunizing children with bronchopulmonary dysplasia in high-risk months.

Reviewers´commentary: palivizumab prophylaxis results in a high cost per episode of hospitalization avoided. There are significant differences depending on the moment of the epidemic season, which in some scenarios may exceed those caused by other risk factors. The recommendations for use should consider this variable to limit the onset and duration of prophylaxis.

How to cite this article

González de Dios J, Ochoa Sangrador C. La inmunización con palivizumab frente al virus respiratorio sincitial solo es coste-efectiva en prematuros con displasia broncopulmonar y en los meses de alto riesgo de la infección. Evid Pediatr. 2010;6:81.

AVC | Critically appraised articles

Rietveld E, Steyerberg EW, Polder JJ, Veeze HJ, Vergouwe Y, Huysman MWA, et al. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis. Arch Dis Child. 2010;95:493-8.
Reviewers: González de Dios J1, Ochoa Sangrador C2.
1Departamento de Pediatría. Hospital General Universitario de Alicante. España.
2Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
Correspondence: Javier González de Dios. Email: javier.gonzalezdedios@gmail.com
Reception date: 10/10/2010
Acceptance date: 19/10/2010
Publication date: 21/10/2010

How to cite this article

González de Dios J, Ochoa Sangrador C. La inmunización con palivizumab frente al virus respiratorio sincitial solo es coste-efectiva en prematuros con displasia broncopulmonar y en los meses de alto riesgo de la infección. Evid Pediatr. 2010;6:81.

References

  1. Rietveld E, Vergouwe Y, Steyerberg EW, Huysman MW, de Groot R, Moll HA; RSV Study Group Southwest Netherlands. Hospitalization for respiratory syncytial virus infection in young children: development of a clinical prediction rule. Pediatr Infect Dis J. 2006;25:201-7.
  2. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1):531-7.
  3. González de Dios J, Ochoa Sangrador C y Grupo de revisión y panel de expertos de la Conferencia de Consenso del Proyecto aBREVIADo (Bronquiolitis-Estudio de Variabilidad, Idoneidad y Adecuación). Guía de práctica clínica Bronquiolitis aguda. Guía Salud 2010 [en línea][fecha de consulta: 4 - X - 2010]. Disponible en: http://www.guiasalud.es/GPC/GPC_463_Bronquiolitis_compl.pdf.
  4. Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med. 2002;156:1034-41.
  5. Wang D, Cummins C, Bayliss S, Sandercock J, Burls A. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess. 2008;12(36): iii, ix-x, 1-86.
  6. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124:1694-701.
  7. Figueras Aloy J, Carbonell Estrany X; Comité de Estándares de la Sociedad Española de Neonatología. Recomendaciones de uso de palivizumab para la prevención de la infección por virus respiratorio sincitial en prematuros de 32 a 35 semanas de gestación. An Pediatr (Barc). 2010;73:98.e1-4.
21/10/2010

Linked Comment